Short Interest in ICU Medical, Inc. (NASDAQ:ICUI) Increases By 14.0%

ICU Medical, Inc. (NASDAQ:ICUI) was the target of a large increase in short interest in January. As of January 15th, there was short interest totalling 838,100 shares, an increase of 14.0% from the December 31st total of 735,400 shares. Based on an average daily volume of 217,900 shares, the days-to-cover ratio is presently 3.8 days. Currently, 3.7% of the company’s stock are short sold.

ICU Medical Stock Performance

Shares of ICUI stock opened at $164.36 on Monday. ICU Medical has a 52 week low of $86.80 and a 52 week high of $196.26. The company has a market capitalization of $4.02 billion, a price-to-earnings ratio of -35.96 and a beta of 0.63. The company has a 50-day simple moving average of $160.98 and a 200 day simple moving average of $162.52. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29.

Insider Buying and Selling

In other ICU Medical news, CEO Vivek Jain sold 1,373 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total transaction of $213,474.04. Following the completion of the transaction, the chief executive officer now owns 104,593 shares in the company, valued at approximately $16,262,119.64. This represents a 1.30 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director David C. Greenberg sold 972 shares of the company’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $158.11, for a total value of $153,682.92. Following the transaction, the director now directly owns 5,037 shares of the company’s stock, valued at $796,400.07. This represents a 16.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 17,737 shares of company stock valued at $2,879,752. 6.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ICU Medical

Institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp boosted its stake in ICU Medical by 9.3% in the 3rd quarter. State Street Corp now owns 907,607 shares of the medical instruments supplier’s stock valued at $165,384,000 after purchasing an additional 77,506 shares during the period. Geode Capital Management LLC boosted its position in shares of ICU Medical by 9.6% in the third quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier’s stock valued at $99,687,000 after acquiring an additional 48,106 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of ICU Medical by 10.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 301,107 shares of the medical instruments supplier’s stock valued at $54,868,000 after acquiring an additional 27,927 shares in the last quarter. WCM Investment Management LLC increased its position in ICU Medical by 1.3% during the third quarter. WCM Investment Management LLC now owns 259,481 shares of the medical instruments supplier’s stock worth $45,272,000 after acquiring an additional 3,407 shares during the period. Finally, Victory Capital Management Inc. raised its stake in ICU Medical by 0.5% in the 3rd quarter. Victory Capital Management Inc. now owns 142,535 shares of the medical instruments supplier’s stock worth $25,973,000 after purchasing an additional 687 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on ICUI shares. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Jefferies Financial Group upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective for the company in a report on Wednesday, December 11th. KeyCorp upped their target price on ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. Finally, Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research note on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $199.67.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.